Thomas Catinazzo is the Chief Financial Officer at Relay Therapeutics Inc., a position he has held since joining the company in 2018. With a robust background in finance and biotechnology, Catinazzo has been instrumental in steering the company's financial strategy and growth. Prior to his role at Relay Therapeutics, he served as the CFO at Merrimack Pharmaceuticals, where he played a key role in managing the company's financial operations and strategic planning. His tenure at Merrimack was marked by successful financings and a sharp focus on maximizing shareholder value. Before his time at Merrimack, Catinazzo held various finance leadership roles at major pharmaceutical companies, including Pfizer and Wyeth. At Pfizer, he was the Vice President of Finance for the company's global research and development division, where he was responsible for financial oversight of a multi-billion-dollar budget. His experience in these roles equipped him with a deep understanding of the financial intricacies involved in drug development and commercialization. Catinazzo's academic credentials include an MBA from the University of Chicago Booth School of Business and a Bachelor's degree in Accounting from Villanova University. In his current role at Relay Therapeutics, Catinazzo oversees all aspects of the company's financial operations, including financial planning and analysis, accounting, and investor relations. His leadership has been pivotal in guiding Relay Therapeutics through its transition from a private to a publicly traded company, culminating in a successful IPO in 2020. Under his stewardship, the company has continued to attract significant investment and forge strategic partnerships, positioning Relay Therapeutics as a leader in the field of precision medicine. Catinazzo's strategic vision and financial acumen continue to drive the company's mission to develop transformative therapies for patients with cancer and other diseases.